UFP Technologies reported a modest 3.4% increase in Q4 sales to $148.9 million, driven by growth in the medical market. While GAAP net income rose to $17.6 million, adjusted EBITDA and adjusted operating income saw declines compared to the prior year, impacted by labor-related inefficiencies at the AJR facility and higher SG&A expenses.

UFP Technologies delivered higher sales in Q3 2025, but net income remained flat due to a $3 million labor-related expense. Adjusted EPS and revenue increased, driven by strength in the MedTech segment.

UFP Technologies posted a robust second quarter, achieving record sales and profitability metrics. Growth was driven by acquisitions and organic expansion in the MedTech segment. Gross margin slightly declined due to labor inefficiencies, but adjusted metrics reflected strong operational leverage.

UFP Technologies, Inc. announced record first-quarter results for 2025, with net income rising to $17.2 million and diluted EPS reaching $2.21. Net sales increased to $148.1 million, up from $105.0 million in the prior year, primarily due to strong growth in the MedTech business.

UFP Technologies reported a strong Q4 2024 with a 41.9% increase in sales and a 41.1% increase in net income compared to the same period in 2023. The company's adjusted EPS grew by 50% to $2.46. The performance of newly acquired companies exceeded expectations, contributing to the overall growth.

UFP Technologies reported a strong Q3 2024 with a 44% increase in sales to $145.2 million and a 40% increase in net income to $16.4 million, driven by organic growth and the performance of recent acquisitions. Gross margins also increased to 28.6%.

UFP Technologies announced record Q2 results with a 10.1% increase in sales, a gross margin growth to 30.0%, and a 14.0% increase in net income. The company also completed three acquisitions expected to add $90 million in revenue and $20 million in EBITDA.

UFP Technologies reported a strong first quarter with a 7.4% organic sales growth in both MedTech and Advanced Components businesses. Operating income and net income increased by 24% and 30%, respectively driven by growth in robotic surgery and infection prevention revenue.

UFP Technologies reported strong Q4 2023 results, with sales reaching $101.5 million, an 11.2% increase year-over-year, and net income of $11.6 million, up from $8.5 million in the same period last year. The company's full-year performance was also impressive, driven by organic growth and strategic acquisitions.

UFP Technologies announced a 13.8% increase in adjusted net income to $11.9 million for Q3 2023, compared to $10.4 million in Q3 2022. Sales for the quarter reached $100.8 million, up from $97.0 million in the same period last year. The company's growth initiatives, including expansion in low-cost country facilities, are progressing, with investments in the Dominican Republic, Costa Rica, and Mexico expected to drive future growth.

UFP Technologies reported a strong second quarter with record results. Sales reached $100.0 million, and net income was $11.9 million, or $1.55 per diluted share. Organic sales grew by 13%, and MedTech sales increased by 16%. Gross margins improved to 29.6%.

UFP Technologies reported a strong Q1 2023, with a 37.2% increase in sales and a near doubling of EPS. The MedTech business was a key driver, particularly robotic surgery, and gross margins improved substantially due to easing cost pressures and improved efficiency.

UFP Technologies reported strong Q4 2022 results with a significant increase in sales and earnings per share compared to the same period in 2021. The company's performance was boosted by recent acquisitions and organic growth, with a positive outlook for the future.

UFP Technologies reported a significant increase in net income and sales for Q3 2022. Sales increased by 91% compared to the prior year, and EPS grew by 412%. The company's performance was boosted by a gain on the sale of its Molded Fiber Technology operation and strong results from recent acquisitions.

UFP Technologies reported a significant increase in sales and net income for Q2 2022. Sales increased to $94.3 million, and net income rose to $8.9 million, or $1.17 per diluted share, compared to the same quarter in the previous year.

UFP Technologies reported a strong first quarter with a 47% increase in revenue compared to Q1 2021, driven by 15% organic growth in the MedTech group. Net income increased to $4.9 million, or $0.64 per diluted share. The company also completed its third acquisition in six months and made progress on new manufacturing capabilities.

UFP Technologies reported a solid Q4 2021 with sales increasing to $56.3 million compared to $45.2 million in Q4 2020. Net income for the quarter was $3.2 million, or $0.42 per diluted share, compared to $4.2 million, or $0.55 per diluted share, in the same period of 2020. The company completed two acquisitions in Q4 and made progress on new operations in Tijuana, Mexico.

UFP Technologies reported a strong Q2 2021 with sales increasing nearly 19% and net income more than doubling compared to the prior year. Sales grew in every market, including Medical, with Automotive and Consumer showing the greatest growth.

UFP Technologies reported a net income of $4.2 million, or $0.55 per diluted share, for Q1 2021, compared to $3.9 million, or $0.52 per diluted share, for the same quarter in 2020. Sales for the quarter were $48.6 million, slightly exceeding the $48.3 million reported in Q1 2020. The company saw strong growth in Aerospace & Defense and Consumer markets, with medical sales showing progress compared to the last two quarters of 2020.

UFP Technologies reported a decrease in sales and net income for Q4 2020 compared to Q4 2019. Sales declined by 10.1% to $45.2 million, and net income decreased by 27.6% to $4.2 million. The company highlighted its cost-cutting initiatives and efficiency improvements, which helped improve gross margins throughout the year. They also managed supply chain issues, kept staff safe, and improved cash balance.

UFP Technologies reported a decrease in sales and net income for Q3 2020 compared to Q3 2019. Sales were $43.3 million, down 12.3% year-over-year, while net income was $3.0 million, or $0.40 per diluted share, compared to $5.6 million, or $0.75 per diluted share in the prior year. However, sales increased 1.5% compared to Q2 2020, and the Advanced Components group experienced strong growth.

UFP Technologies reported a decrease in net income and sales for Q2 2020 compared to Q2 2019, primarily due to the adverse impacts of COVID-19 on its various markets. Despite the challenges, the company's product development business showed strong growth, and the company maintained a solid cash balance.

UFP Technologies announced Q1 2020 results with a 2% increase in sales and a 4% increase in net income compared to Q1 2019. The company's medical sales grew significantly, offsetting declines in non-medical markets due to the COVID-19 pandemic.

UFP Technologies reported a slight decrease in sales but an increase in net income for Q4 2019 compared to Q4 2018. Full year results showed significant growth in revenue, operating income, and net income, driven by increased medical sales and improved operating efficiency.